Abstract:The p53 protein is the master regulator of cellular integrity, primarily due to its tumor-suppressing functions. Approximately half of all human cancers carry mutations in the TP53 gene, which not only abrogate the tumor-suppressive functions but also confer p53 mutant proteins with oncogenic potential. The latter is achieved through so-called gain-of-function (GOF) mutations that promote cancer progression, metastasis, and therapy resistance by deregulating transcriptional networks, signaling pathways, metabolism, immune surveillance, and cellular compositions of the microenvironment. Despite recent progress in understanding the complexity of mutp53 in neoplastic development, the exact mechanisms of how mutp53 contributes to cancer development and how they escape proteasomal and lysosomal degradation remain only partially understood. In this review, we address recent findings in the field of oncogenic functions of mutp53 specifically regarding, but not limited to, its implications in metabolic pathways, the secretome of cancer cells, the cancer microenvironment, and the regulating scenarios of the aberrant proteasomal degradation. By analyzing proteasomal and lysosomal protein degradation, as well as its connection with autophagy, we propose new therapeutical approaches that aim to destabilize mutp53 proteins and deactivate its oncogenic functions, thereby providing a fundamental basis for further investigation and rational treatment approaches for TP53-mutated cancers.

What problem does this paper attempt to address?

### What problem does this paper attempt to solve? This paper primarily explores the new mechanisms of action, degradation pathways, and therapeutic interventions of mutant p53 (mutp53) in cancer. Specifically: 1. **New Oncogenic Functions of Mutant p53**: - Mutant p53 not only loses its original tumor suppressor function but also gains new oncogenic functions (gain-of-function, GOF), promoting cancer development, metastasis, and drug resistance through the regulation of various metabolic pathways, signaling pathways, and immune surveillance. - The research focuses on the impact of mutant p53 on metabolic pathways such as glycolysis, amino acid metabolism, and nucleotide metabolism, and how these changes affect the behavior of cancer cells. 2. **Regulation of the Cancer Secretome**: - Mutant p53 significantly alters the secretome of cancer cells, including exosomes, cytokines, and other metabolic products, thereby affecting intercellular communication within the tumor microenvironment (TME). - Particularly in pancreatic ductal adenocarcinoma (PDAC), different variants of mutant p53 (such as R175H and R273H) have distinct effects on the cellular secretome, promoting tumor progression, chemotherapy resistance, apoptosis, and epithelial-mesenchymal transition (EMT). 3. **Remodeling of the Tumor Microenvironment (TME)**: - Mutant p53 influences the secretion of extracellular vesicles (EVs), affecting the activation of cancer-associated fibroblasts (CAFs), extracellular matrix (ECM) remodeling, and angiogenesis within the tumor microenvironment, thereby promoting tumor growth and metastasis. - These vesicles carry mutant p53, transmitting oncogenic properties to neighboring cells, further supporting tumor development. 4. **Degradation Pathways of Mutant p53**: - The paper analyzes the degradation pathways of mutant p53 in the proteasome and lysosome and explores the role of autophagy in this process. - It proposes targeting heat shock protein (HSP) expression and post-translational modifications to disrupt the stability of mutant p53 and inhibit its oncogenic functions, providing a theoretical basis for treating mutant p53-related cancers. In summary, this paper aims to comprehensively explore the complex roles of mutant p53 in cancer, revealing its new mechanisms in metabolic reprogramming, secretome alteration, TME remodeling, and degradation pathways, and proposes corresponding therapeutic strategies.

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions

Mutant p53 in Cancer Progression and Targeted Therapies

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Mutant p53 as a guardian of the cancer cell

Mutant p53 in cancer therapy-the barrier or the path.

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

Resuscitating the Guardian: Current Progress in P53-Based Anti-Tumor Therapy

Functional Diversity of P53 in Human and Wild Animals

Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

Gain-of-function mutant p53 in cancer progression and therapy

Mutations of p53 associated with pancreatic cancer and therapeutic implications

Translating p53-based therapies for cancer into the clinic

p53 signaling in cancer progression and therapy

Tumor Suppressor P53 and Its Gain-of-function Mutants in Cancer

Regulation of P53 Stability As a Therapeutic Strategy for Cancer.